HomeCompareSNBIF vs MO

SNBIF vs MO: Dividend Comparison 2026

SNBIF yields 12.16% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $35.5K in total portfolio value· pulled ahead in Year 8
10 years
SNBIF
SNBIF
● Live price
12.16%
Share price
$16.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.6K
Annual income
$2,595.30
Full SNBIF calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — SNBIF vs MO

📍 MO pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNBIFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNBIF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNBIF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNBIF
Annual income on $10K today (after 15% tax)
$1,033.43/yr
After 10yr DRIP, annual income (after tax)
$2,206.01/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, MO beats the other by $23,429.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNBIF + MO for your $10,000?

SNBIF: 50%MO: 50%
100% MO50/50100% SNBIF
Portfolio after 10yr
$62.4K
Annual income
$16,377.23/yr
Blended yield
26.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

SNBIF
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
60.9
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNBIF buys
0
MO buys
0
No recent congressional trades found for SNBIF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNBIFMO
Forward yield12.16%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$44.6K$80.1K
Annual income after 10y$2,595.30$30,159.17
Total dividends collected$18.9K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusSellBuy

Year-by-year: SNBIF vs MO ($10,000, DRIP)

YearSNBIF PortfolioSNBIF Income/yrMO PortfolioMO Income/yrGap
1$11,916$1,215.81$10,570$780.30+$1.3KSNBIF
2$14,104$1,353.95$11,381$1,032.90+$2.7KSNBIF
3$16,589$1,497.73$12,535$1,392.73+$4.1KSNBIF
4$19,396$1,646.38$14,193$1,920.91+$5.2KSNBIF
5$22,553$1,799.08$16,618$2,723.68+$5.9KSNBIF
6$26,087$1,955.04$20,263$3,993.80+$5.8KSNBIF
7$30,027$2,113.43$25,936$6,098.36+$4.1KSNBIF
8← crossover$34,402$2,273.44$35,166$9,775.01$764.00MO
9$39,244$2,434.31$51,026$16,597.78$11.8KMO
10$44,587$2,595.30$80,113$30,159.17$35.5KMO

SNBIF vs MO: Complete Analysis 2026

SNBIFStock

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

Full SNBIF Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this SNBIF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNBIF vs SCHDSNBIF vs JEPISNBIF vs OSNBIF vs KOSNBIF vs MAINSNBIF vs PMSNBIF vs BTISNBIF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.